XOMA Co. (NASDAQ:XOMA) Shares Sold by HighVista Strategies LLC

HighVista Strategies LLC trimmed its holdings in shares of XOMA Co. (NASDAQ:XOMA) by 3.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 114,548 shares of the biotechnology company’s stock after selling 4,351 shares during the period. XOMA comprises 1.0% of HighVista Strategies LLC’s investment portfolio, making the stock its 28th largest position. HighVista Strategies LLC owned 0.97% of XOMA worth $3,033,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. BNP Paribas Financial Markets raised its stake in shares of XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 795 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in shares of XOMA during the first quarter worth about $212,000. Rhumbline Advisers boosted its position in shares of XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after buying an additional 1,334 shares during the period. Ellsworth Advisors LLC acquired a new stake in shares of XOMA in the third quarter valued at about $516,000. Finally, Bank of New York Mellon Corp grew its stake in shares of XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after buying an additional 1,968 shares in the last quarter. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a report on Wednesday, August 14th. HC Wainwright reissued a “buy” rating and set a $123.00 target price (up from $117.00) on shares of XOMA in a research report on Monday.

XOMA Stock Performance

NASDAQ:XOMA opened at $32.43 on Tuesday. XOMA Co. has a one year low of $14.77 and a one year high of $35.00. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. The business’s 50-day simple moving average is $29.48 and its 200 day simple moving average is $27.42.

Insiders Place Their Bets

In other news, CEO Owen Hughes sold 21,881 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total transaction of $655,335.95. Following the completion of the sale, the chief executive officer now owns 34,979 shares of the company’s stock, valued at approximately $1,047,621.05. This trade represents a 38.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.20% of the stock is owned by company insiders.

XOMA Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.